Invest New Drugs (2014) 32:388
DOI 10.1007/s10637-013-0021-1

ERRATUM

Erratum to: Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics

Yu Sunakawa · Junji Furuse · Takuji Okusaka · Masafumi Ikeda · Fumio Nagashima · Hideki Ueno · Shuichi Mitsunaga · Kensei Hashizume · Yuichiro Ito · Yasutsuna Sasaki

Published online: 3 September 2013

Erratum to: Invest New Drugs
DOI 10.1007/s10637-013-9953-8

Following online publication of this article, some factual and typographical errors have been identified; the correct details are as follows: In the results section (safety subsection), the rate of leukopenia was 27 % (not 33 %), and four patients experienced grade 3 lymphopenia (not five patients). In the efficacy subsection, the duration of response should be 10.4 months (not 10.5 months). In Table 2, the rate of any-grade proteinuria should be 80 % (not 8 %). In Table 4, the AUC0–24 for the M5 metabolite should be 380.0 (164.2) μg.h/L (not 380.5/164.2(112.0)).

The online version of the original article can be found at http://dx.doi.org/10.1007/s10637-013-9953-8.

Y. Sunakawa (✉)
International Medical Center-Comprehensive Cancer Center, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan
e-mail: y.suna0825@gmail.com

J. Furuse · F. Nagashima
Department of Medical Oncology, Kyorin University, School of Medicine, Tokyo, Japan

T. Okusaka · H. Ueno
Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan

M. Ikeda · S. Mitsunaga
Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan

K. Hashizume
Global Drug Discovery, Clinical Pharmacology, Bayer Yakuhin, Ltd., Osaka, Japan

Y. Ito
Product Development Department, Bayer Yakuhin, Ltd., Osaka, Japan

Y. Sasaki
Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan